- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02816151
Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses (TBIDE)
Study Overview
Status
Conditions
Detailed Description
The main aim of the study is to so determine dosages with mid--amount of TBA would make it possible to anticipate not-inferiors results with full posology and to determine the benefit ratio/risk improvement. This could lead to an important reduction of the treatment costs. This study also aims to better identy the "non responders" patients in order to refine the indications. Thanks to the participation of a French urologic paediatric surgery centers, the study hope to homogenize practices and to use standardized common criteria of judgement.
Lastly, this study should appreciate if it is possible not to more bring back posology to the weight of the child, but on detrusor surface allowing a more precise estimation of the amounts to be managed.
A complementary study on the quality of life of these children before and after treatment will be carried out thanks to Child Health Questionnaire (CHQ 50). The diagram of the study is a randomized therapeutic test controlled not-inferiority aiming at comparing an amount full versus an half-amount with TBA.
The population of the study will be made up children from 3 to 15 years treated for detrusor hyperactivity, confirmed by an aurodynamic assessment according to the criteria of International the Society Continence, origin neurological, and resistant to the medical care associated with the usual accompanying measures.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Reims
-
France, Reims, France, 51092
- Chu Reims
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
inclusion criteria
- Old ≥3 years and ≤15 years
- Syndrome of vesical hyperactivity associated with a manometric detrusor hyperactivity
- Neurogenic vesico-sphincter disorders
- Anticholinergic treatment total/partial Failure/ intolerance
- Native Bladder and TB virgin
- Bladder patient or ready to be it, or possibly straight bladder
- 3 months delay if TB injection in another site
- Agreement to stop anticholinergic treatment 1 month before and throughout all protocol
non- inclusion criteria
- Toxin Botulinic use counter-indication (myasthenia, infantil spinal amyotrophy)
- General anaesthesia counter-indication
- Haemostasis disorders
- Children less than 3 years and more than 16 years
- non-neurogenic vesical hyperactivity
- Good tolerance and effectiveness of the anticholinergic treatment
- Bladder increased or already treated by one or more Toxin injections
- Having toxin injection in another site since less than 3 months
- Child wouldn't sondered
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 2
|
Intradetrusor injection under general anesthesia.
Injection done through 25 points of 1cc each.
|
Experimental: Group 1
|
Intradetrusor injection under general anesthesia.
Injection done through 25 points of 1cc each.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detrusor pression decrease in neurogenic vesical hyperactivity syndrom for child
Time Frame: up to 6 weeks after intradetrusor injection
|
maximal vesical capacity and maximal pression at the end of filling mesured during the course of cystomanometry exam.
These points were mesured at leak point or bladder point or when pain appear
|
up to 6 weeks after intradetrusor injection
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Dyskinesias
- Hyperkinesis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Cholinergic Agents
- Membrane Transport Modulators
- Acetylcholine Release Inhibitors
- Neuromuscular Agents
- Botulinum Toxins, Type A
- abobotulinumtoxinA
Other Study ID Numbers
- PN10002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.